Curis (NASDAQ:CRIS) +4.2% premarket on news the drug developer has earned a $350K milestone payment from the Leukemia and Lymphoma Society after starting a Phase I clinical trial study of a refractory lymphoma and multiple myeloma treatment.
Curis (NASDAQ:CRIS) +4.2% premarket on news the drug developer has earned a $350K milestone payment from the Leukemia and Lymphoma Society after starting a Phase I clinical trial study of a refractory lymphoma and multiple myeloma treatment.